Furthermore, mutations in the genes belonging to the PI3 kinase pathway (PIK3CA, AKT1, and PTEN) in triple-negative BC patients may be treated with AKT inhibitors like Ipatasertib and Capivasertib. Here, AKT1 is linked to breast cancer.